EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors

Christopher H Evans, Fangjun Liu, Ryan M. Porter, Regina P. O'Sullivan, Taha Merghoub, Elaine P. Lunsford, Kyle Robichaud, Frans Van Valen, Stephen L. Lessnick, Mark C. Gebhardt, James W. Wells

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: The Ewing sarcoma family of tumors (ESFT) comprises a group of aggressive, malignant bone, and soft tissue tumors that predominantly affect children and young adults. These tumors frequently share expression of the EWS-FLI-1 translocation, which is central to tumor survival but not present in healthy cells. In this study, we examined EWS-FLI-1 antigens for their capacity to induce immunity against a range of ESFT types. Design: Computer prediction analysis of peptide binding, HLA-A2.1 stabilization assays, and induction of cytotoxic T-lymphocytes (CTL) in immunized HLA-A2.1 transgenic mice were used to assess the immunogenicity of native and modified peptides derived from the fusion region of EWS-FLI-1 type 1. CTL-killing of multiple ESFT family members in vitro, and control of established xenografts in vivo, was assessed. We also examined whether these peptides could induce human CTLs in vitro. Results: EWS-FLI-1 type 1 peptides were unable to stabilize cell surface HLA-A2.1 and induced weak CTL activity against Ewing sarcoma cells. In contrast, peptides with modified anchor residues induced potent CTL killing of Ewing sarcoma cells presenting endogenous (native) peptides. The adoptive transfer of CTL specific for the modified peptide YLNPSVDSV resulted in enhanced survival of mice with established Ewing sarcoma xenografts. YLNPSVDSV-specific CTL displayed potent killing of multiple ESFT types in vitro : Ewing sarcoma, pPNET, Askin's Tumor, and Biphenotypic sarcoma. Stimulation of human peripheral blood mononuclear cells with YLNPSVDSV peptide resulted in potent CTL-killing. Conclusions: These data show that YLNPSVDSV peptide is a promising antigen for ESFT immunotherapy and warrants further clinical development.

Original languageEnglish (US)
Pages (from-to)5341-5351
Number of pages11
JournalClinical Cancer Research
Volume18
Issue number19
DOIs
StatePublished - Oct 1 2012
Externally publishedYes

Fingerprint

Ewing's Sarcoma
Cytotoxic T-Lymphocytes
T-Lymphocytes
Peptides
Neoplasms
Heterografts
EWS-FLI fusion protein
Antigens
Adoptive Transfer
Sarcoma
Immunotherapy
Transgenic Mice
Young Adult
Immunity
Blood Cells
Bone and Bones
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors. / Evans, Christopher H; Liu, Fangjun; Porter, Ryan M.; O'Sullivan, Regina P.; Merghoub, Taha; Lunsford, Elaine P.; Robichaud, Kyle; Van Valen, Frans; Lessnick, Stephen L.; Gebhardt, Mark C.; Wells, James W.

In: Clinical Cancer Research, Vol. 18, No. 19, 01.10.2012, p. 5341-5351.

Research output: Contribution to journalArticle

Evans, CH, Liu, F, Porter, RM, O'Sullivan, RP, Merghoub, T, Lunsford, EP, Robichaud, K, Van Valen, F, Lessnick, SL, Gebhardt, MC & Wells, JW 2012, 'EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors', Clinical Cancer Research, vol. 18, no. 19, pp. 5341-5351. https://doi.org/10.1158/1078-0432.CCR-12-1985
Evans, Christopher H ; Liu, Fangjun ; Porter, Ryan M. ; O'Sullivan, Regina P. ; Merghoub, Taha ; Lunsford, Elaine P. ; Robichaud, Kyle ; Van Valen, Frans ; Lessnick, Stephen L. ; Gebhardt, Mark C. ; Wells, James W. / EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 19. pp. 5341-5351.
@article{79e9ea06c4744a5697e1ac59a505fb22,
title = "EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors",
abstract = "Purpose: The Ewing sarcoma family of tumors (ESFT) comprises a group of aggressive, malignant bone, and soft tissue tumors that predominantly affect children and young adults. These tumors frequently share expression of the EWS-FLI-1 translocation, which is central to tumor survival but not present in healthy cells. In this study, we examined EWS-FLI-1 antigens for their capacity to induce immunity against a range of ESFT types. Design: Computer prediction analysis of peptide binding, HLA-A2.1 stabilization assays, and induction of cytotoxic T-lymphocytes (CTL) in immunized HLA-A2.1 transgenic mice were used to assess the immunogenicity of native and modified peptides derived from the fusion region of EWS-FLI-1 type 1. CTL-killing of multiple ESFT family members in vitro, and control of established xenografts in vivo, was assessed. We also examined whether these peptides could induce human CTLs in vitro. Results: EWS-FLI-1 type 1 peptides were unable to stabilize cell surface HLA-A2.1 and induced weak CTL activity against Ewing sarcoma cells. In contrast, peptides with modified anchor residues induced potent CTL killing of Ewing sarcoma cells presenting endogenous (native) peptides. The adoptive transfer of CTL specific for the modified peptide YLNPSVDSV resulted in enhanced survival of mice with established Ewing sarcoma xenografts. YLNPSVDSV-specific CTL displayed potent killing of multiple ESFT types in vitro : Ewing sarcoma, pPNET, Askin's Tumor, and Biphenotypic sarcoma. Stimulation of human peripheral blood mononuclear cells with YLNPSVDSV peptide resulted in potent CTL-killing. Conclusions: These data show that YLNPSVDSV peptide is a promising antigen for ESFT immunotherapy and warrants further clinical development.",
author = "Evans, {Christopher H} and Fangjun Liu and Porter, {Ryan M.} and O'Sullivan, {Regina P.} and Taha Merghoub and Lunsford, {Elaine P.} and Kyle Robichaud and {Van Valen}, Frans and Lessnick, {Stephen L.} and Gebhardt, {Mark C.} and Wells, {James W.}",
year = "2012",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-12-1985",
language = "English (US)",
volume = "18",
pages = "5341--5351",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors

AU - Evans, Christopher H

AU - Liu, Fangjun

AU - Porter, Ryan M.

AU - O'Sullivan, Regina P.

AU - Merghoub, Taha

AU - Lunsford, Elaine P.

AU - Robichaud, Kyle

AU - Van Valen, Frans

AU - Lessnick, Stephen L.

AU - Gebhardt, Mark C.

AU - Wells, James W.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Purpose: The Ewing sarcoma family of tumors (ESFT) comprises a group of aggressive, malignant bone, and soft tissue tumors that predominantly affect children and young adults. These tumors frequently share expression of the EWS-FLI-1 translocation, which is central to tumor survival but not present in healthy cells. In this study, we examined EWS-FLI-1 antigens for their capacity to induce immunity against a range of ESFT types. Design: Computer prediction analysis of peptide binding, HLA-A2.1 stabilization assays, and induction of cytotoxic T-lymphocytes (CTL) in immunized HLA-A2.1 transgenic mice were used to assess the immunogenicity of native and modified peptides derived from the fusion region of EWS-FLI-1 type 1. CTL-killing of multiple ESFT family members in vitro, and control of established xenografts in vivo, was assessed. We also examined whether these peptides could induce human CTLs in vitro. Results: EWS-FLI-1 type 1 peptides were unable to stabilize cell surface HLA-A2.1 and induced weak CTL activity against Ewing sarcoma cells. In contrast, peptides with modified anchor residues induced potent CTL killing of Ewing sarcoma cells presenting endogenous (native) peptides. The adoptive transfer of CTL specific for the modified peptide YLNPSVDSV resulted in enhanced survival of mice with established Ewing sarcoma xenografts. YLNPSVDSV-specific CTL displayed potent killing of multiple ESFT types in vitro : Ewing sarcoma, pPNET, Askin's Tumor, and Biphenotypic sarcoma. Stimulation of human peripheral blood mononuclear cells with YLNPSVDSV peptide resulted in potent CTL-killing. Conclusions: These data show that YLNPSVDSV peptide is a promising antigen for ESFT immunotherapy and warrants further clinical development.

AB - Purpose: The Ewing sarcoma family of tumors (ESFT) comprises a group of aggressive, malignant bone, and soft tissue tumors that predominantly affect children and young adults. These tumors frequently share expression of the EWS-FLI-1 translocation, which is central to tumor survival but not present in healthy cells. In this study, we examined EWS-FLI-1 antigens for their capacity to induce immunity against a range of ESFT types. Design: Computer prediction analysis of peptide binding, HLA-A2.1 stabilization assays, and induction of cytotoxic T-lymphocytes (CTL) in immunized HLA-A2.1 transgenic mice were used to assess the immunogenicity of native and modified peptides derived from the fusion region of EWS-FLI-1 type 1. CTL-killing of multiple ESFT family members in vitro, and control of established xenografts in vivo, was assessed. We also examined whether these peptides could induce human CTLs in vitro. Results: EWS-FLI-1 type 1 peptides were unable to stabilize cell surface HLA-A2.1 and induced weak CTL activity against Ewing sarcoma cells. In contrast, peptides with modified anchor residues induced potent CTL killing of Ewing sarcoma cells presenting endogenous (native) peptides. The adoptive transfer of CTL specific for the modified peptide YLNPSVDSV resulted in enhanced survival of mice with established Ewing sarcoma xenografts. YLNPSVDSV-specific CTL displayed potent killing of multiple ESFT types in vitro : Ewing sarcoma, pPNET, Askin's Tumor, and Biphenotypic sarcoma. Stimulation of human peripheral blood mononuclear cells with YLNPSVDSV peptide resulted in potent CTL-killing. Conclusions: These data show that YLNPSVDSV peptide is a promising antigen for ESFT immunotherapy and warrants further clinical development.

UR - http://www.scopus.com/inward/record.url?scp=84866913471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866913471&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-1985

DO - 10.1158/1078-0432.CCR-12-1985

M3 - Article

C2 - 22879388

AN - SCOPUS:84866913471

VL - 18

SP - 5341

EP - 5351

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19

ER -